Medtide

Medtide Intangible Assets

The Intangible Assets of Medtide (3880.HK) as of Oct 22, 2026 is 36.02 M CNY. In the previous year, Intangible Assets was 41.09 M CNY — a change of -12.35% (lower).

Intangible Assets

36.02 MCNY

YoY

-12.35%

Last updated:

Intangible Assets of Medtide is 2024 36.02 M CNY. Intangible Assets of Medtide was 2023 41.09 M CNY. It decreases by -12.35% lower compared to the previous year.

The Medtide Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2022
47.01 M CNY
Jan 1, 2023
41.09 M CNY
Jan 1, 2024
36.02 M CNY
The Medtide Intangible Assets history
YEARIntangible AssetsYoY
36.02 MCNY-12.35%
41.09 MCNY-12.60%
47.01 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

Intangible Assets of Medtide is 36.02 M CNY in 2024.

Intangible Assets of Medtide changed from 41.09 M CNY to 36.02 M CNY, representing a -12.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Medtide since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Medtide historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Medtide

All Key Metrics — Medtide